Literature DB >> 26018073

Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models.

Mikhail A Kostylev1, Adam C Kaufman1, Haakon B Nygaard2, Pujan Patel1, Laura T Haas1, Erik C Gunther2, Alexander Vortmeyer3, Stephen M Strittmatter4.   

Abstract

Alzheimer disease (AD) is characterized by amyloid-β accumulation, with soluble oligomers (Aβo) being the most synaptotoxic. However, the multivalent and unstable nature of Aβo limits molecular characterization and hinders research reproducibility. Here, we characterized multiple Aβo forms throughout the life span of various AD mice and in post-mortem human brain. Aβo exists in several populations, where prion protein (PrP(C))-interacting Aβo is a high molecular weight Aβ assembly present in multiple mice and humans with AD. Levels of PrP(C)-interacting Aβo match closely with mouse memory and are equal or superior to other Aβ measures in predicting behavioral impairment. However, Aβo metrics vary considerably between mouse strains. Deleting PrP(C) expression in mice with relatively low PrP(C)-interacting Aβo (Tg2576) results in partial rescue of cognitive performance as opposed to complete recovery in animals with a high percentage of PrP(C)-interacting Aβo (APP/PSEN1). These findings highlight the relative contributions and interplay of Aβo forms in AD.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Alzheimer disease; amyloid-beta (AB); learn; ligand-binding protein; memory; oligomer; prion; transgenic mice

Mesh:

Substances:

Year:  2015        PMID: 26018073      PMCID: PMC4498078          DOI: 10.1074/jbc.M115.643577

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  86 in total

1.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

3.  The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.

Authors:  Ulrike K Resenberger; Anja Harmeier; Andreas C Woerner; Jessica L Goodman; Veronika Müller; Rajaraman Krishnan; R Martin Vabulas; Hans A Kretzschmar; Susan Lindquist; F Ulrich Hartl; Gerd Multhaup; Konstanze F Winklhofer; Jörg Tatzelt
Journal:  EMBO J       Date:  2011-03-25       Impact factor: 11.598

4.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

Authors:  Stefan Barghorn; Volker Nimmrich; Andreas Striebinger; Carsten Krantz; Patrick Keller; Bodo Janson; Michael Bahr; Martin Schmidt; Robert S Bitner; John Harlan; Eve Barlow; Ulrich Ebert; Heinz Hillen
Journal:  J Neurochem       Date:  2005-08-31       Impact factor: 5.372

5.  Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death.

Authors:  Wataru Kudo; Hyun-Pil Lee; Wen-Quan Zou; Xinglong Wang; George Perry; Xiongwei Zhu; Mark A Smith; Robert B Petersen; Hyoung-gon Lee
Journal:  Hum Mol Genet       Date:  2011-11-18       Impact factor: 6.150

6.  Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins.

Authors:  Clive Bate; Alun Williams
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

Review 7.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

8.  Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Aβ synaptotoxicity.

Authors:  Igor Klyubin; Andrew J Nicoll; Azadeh Khalili-Shirazi; Michael Farmer; Stephanie Canning; Alexandra Mably; Jacqueline Linehan; Alexander Brown; Madeleine Wakeling; Sebastian Brandner; Dominic M Walsh; Michael J Rowan; John Collinge
Journal:  J Neurosci       Date:  2014-04-30       Impact factor: 6.167

9.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

10.  Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1.

Authors:  Jo V Rushworth; Heledd H Griffiths; Nicole T Watt; Nigel M Hooper
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

View more
  49 in total

Review 1.  Actin dynamics and cofilin-actin rods in alzheimer disease.

Authors:  James R Bamburg; Barbara W Bernstein
Journal:  Cytoskeleton (Hoboken)       Date:  2016-03-01

2.  Alterations in Striatal microRNA-mRNA Networks Contribute to Neuroinflammation in Multiple System Atrophy.

Authors:  Taeyeon Kim; Elvira Valera; Paula Desplats
Journal:  Mol Neurobiol       Date:  2019-04-09       Impact factor: 5.590

3.  [Effect of intrahippocampal injection of anti-cellular prion protein monoclonal antibody on cognitive deficits in APPswe/PSEN1dE9 transgenic mice].

Authors:  Hai-Ying Zhang; Yi-Heng Liu; Yuan Fu; Peng-Cheng Chen; Rui Lu; Jian-Xing Li; Ming-Hui Chen; Hao-Chi Yang; Yu-Sheng Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

4.  Pyk2 Signaling through Graf1 and RhoA GTPase Is Required for Amyloid-β Oligomer-Triggered Synapse Loss.

Authors:  Suho Lee; Santiago V Salazar; Timothy O Cox; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2019-01-09       Impact factor: 6.167

Review 5.  Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease.

Authors:  Santiago V Salazar; Stephen M Strittmatter
Journal:  Biochem Biophys Res Commun       Date:  2016-09-14       Impact factor: 3.575

6.  Liquid and Hydrogel Phases of PrPC Linked to Conformation Shifts and Triggered by Alzheimer's Amyloid-β Oligomers.

Authors:  Mikhail A Kostylev; Marcus D Tuttle; Suho Lee; Lauren E Klein; Hideyuki Takahashi; Timothy O Cox; Erik C Gunther; Kurt W Zilm; Stephen M Strittmatter
Journal:  Mol Cell       Date:  2018-10-25       Impact factor: 17.970

7.  The membrane axis of Alzheimer's nanomedicine.

Authors:  Yuhuan Li; Huayuan Tang; Nicholas Andrikopoulos; Ibrahim Javed; Luca Cecchetto; Aparna Nandakumar; Aleksandr Kakinen; Thomas P Davis; Feng Ding; Pu Chun Ke
Journal:  Adv Nanobiomed Res       Date:  2020-11-26

8.  The cellular prion protein (PrPC) as neuronal receptor for α-synuclein.

Authors:  Laura Urrea; Isidro Ferrer; Rosalina Gavín; José Antonio Del Río
Journal:  Prion       Date:  2017-07-31       Impact factor: 3.931

9.  Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists.

Authors:  Erik C Gunther; Levi M Smith; Mikhail A Kostylev; Timothy O Cox; Adam C Kaufman; Suho Lee; Ewa Folta-Stogniew; George D Maynard; Ji Won Um; Massimiliano Stagi; Jacqueline K Heiss; Austin Stoner; Geoff P Noble; Hideyuki Takahashi; Laura T Haas; John S Schneekloth; Janie Merkel; Christopher Teran; Zahra K Naderi; Surachai Supattapone; Stephen M Strittmatter
Journal:  Cell Rep       Date:  2019-01-02       Impact factor: 9.423

Review 10.  Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity.

Authors:  Levi M Smith; Stephen M Strittmatter
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.